PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Transatlantique Private Wealth LLC

Transatlantique Private Wealth LLC lowered its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 18.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 118,436 shares of the company’s stock after selling 26,175 shares during the quarter. PROCEPT BioRobotics accounts for about 3.6% of Transatlantique Private Wealth LLC’s investment portfolio, making the stock its 3rd largest position. Transatlantique Private Wealth LLC owned about 0.23% of PROCEPT BioRobotics worth $9,536,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. HighTower Advisors LLC acquired a new position in shares of PROCEPT BioRobotics during the third quarter valued at about $279,000. Wilmington Savings Fund Society FSB acquired a new position in PROCEPT BioRobotics in the 3rd quarter valued at approximately $64,000. Franklin Resources Inc. lifted its position in shares of PROCEPT BioRobotics by 64.5% in the 3rd quarter. Franklin Resources Inc. now owns 885,992 shares of the company’s stock worth $64,669,000 after acquiring an additional 347,330 shares during the period. Lord Abbett & CO. LLC lifted its position in shares of PROCEPT BioRobotics by 45.3% in the 3rd quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company’s stock worth $59,974,000 after acquiring an additional 233,430 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of PROCEPT BioRobotics by 290.2% during the 3rd quarter. Principal Financial Group Inc. now owns 68,617 shares of the company’s stock worth $5,498,000 after purchasing an additional 51,030 shares in the last quarter. 89.46% of the stock is owned by institutional investors.

Insider Activity

In related news, CFO Kevin Waters sold 733 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares of the company’s stock, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares of the company’s stock, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,455 shares of company stock worth $368,322. Insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock opened at $53.03 on Friday. The firm has a market capitalization of $2.91 billion, a P/E ratio of -27.19 and a beta of 1.09. The stock has a fifty day moving average price of $59.16 and a two-hundred day moving average price of $74.66. PROCEPT BioRobotics Co. has a 52-week low of $47.04 and a 52-week high of $103.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The firm had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. As a group, analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the company. Morgan Stanley reduced their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Truist Financial reduced their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating for the company in a report on Friday, April 11th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.43.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).